Vitrolife acquires 25% participation in HertART Aps

Vitrolife (STO:VITR) has entered an agreement with the Danish company HertART Aps with regard to product development and distribution of IVF products and at the same time acquires a participation of 25 percent in the company.

HertART works with high quality and registered products within IVF (In Vitro Fertilization) / ART (Assisted Reproductive Technologies). "The collaboration will mainly concern products for in vitro fertilization but is of fundamental importance as there are points of contact primarily in the stem cell business area. We see the collaboration with HertART as an opportunity to fill our research and development portfolio more quickly within the framework of our long-term development objectives," says Tony Winslöf, Head of Business Development at Vitrolife.

Vitrolife is acquiring 25 percent of the shares in the company, with an option to acquire up to 100 percent. The purchase sum amounts to DKK 2.0 million. For the Vitrolife Group as a whole, the acquisition will initially have a marginal effect on income and sales.